JP7393207B2 - 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 - Google Patents

抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 Download PDF

Info

Publication number
JP7393207B2
JP7393207B2 JP2019561267A JP2019561267A JP7393207B2 JP 7393207 B2 JP7393207 B2 JP 7393207B2 JP 2019561267 A JP2019561267 A JP 2019561267A JP 2019561267 A JP2019561267 A JP 2019561267A JP 7393207 B2 JP7393207 B2 JP 7393207B2
Authority
JP
Japan
Prior art keywords
seq
nos
amino acid
adi
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019561267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518650A (ja
JP2020518650A5 (enExample
Inventor
ローラ エム． ウォーカー，
ロバート ペチャル，
エリック クラウランド，
マキシミリアーノ バスケス，
モニカ ワイ リン レオン，
Original Assignee
アディマブ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アディマブ， エルエルシー filed Critical アディマブ， エルエルシー
Publication of JP2020518650A publication Critical patent/JP2020518650A/ja
Publication of JP2020518650A5 publication Critical patent/JP2020518650A5/ja
Priority to JP2022193173A priority Critical patent/JP7641262B2/ja
Application granted granted Critical
Publication of JP7393207B2 publication Critical patent/JP7393207B2/ja
Priority to JP2024014044A priority patent/JP2024032937A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019561267A 2017-05-08 2018-05-08 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 Active JP7393207B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022193173A JP7641262B2 (ja) 2017-05-08 2022-12-01 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法
JP2024014044A JP2024032937A (ja) 2017-05-08 2024-02-01 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762503315P 2017-05-08 2017-05-08
US62/503,315 2017-05-08
PCT/US2018/031705 WO2018208864A1 (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022193173A Division JP7641262B2 (ja) 2017-05-08 2022-12-01 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法

Publications (3)

Publication Number Publication Date
JP2020518650A JP2020518650A (ja) 2020-06-25
JP2020518650A5 JP2020518650A5 (enExample) 2021-05-27
JP7393207B2 true JP7393207B2 (ja) 2023-12-06

Family

ID=64104990

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019561267A Active JP7393207B2 (ja) 2017-05-08 2018-05-08 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法
JP2022193173A Active JP7641262B2 (ja) 2017-05-08 2022-12-01 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法
JP2024014044A Pending JP2024032937A (ja) 2017-05-08 2024-02-01 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022193173A Active JP7641262B2 (ja) 2017-05-08 2022-12-01 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法
JP2024014044A Pending JP2024032937A (ja) 2017-05-08 2024-02-01 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法

Country Status (12)

Country Link
US (2) US11542330B2 (enExample)
EP (1) EP3621641A4 (enExample)
JP (3) JP7393207B2 (enExample)
KR (2) KR20250121461A (enExample)
CN (4) CN118894936A (enExample)
AU (2) AU2018266711B2 (enExample)
BR (1) BR112019023111A2 (enExample)
CA (1) CA3062825A1 (enExample)
IL (2) IL322042A (enExample)
MX (2) MX2019013184A (enExample)
SG (2) SG11201910096RA (enExample)
WO (1) WO2018208864A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014973A (es) * 2019-06-07 2022-04-18 Adimab Llc Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
CN119874917A (zh) * 2019-06-07 2025-04-25 阿迪马布有限责任公司 工程化的pH依赖性抗CD3抗体及其产生和使用方法
US20220227887A1 (en) * 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant
JP2022544405A (ja) 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
KR20220045030A (ko) * 2019-08-17 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도
US20210087271A1 (en) * 2019-09-20 2021-03-25 Adimab, Llc Fc variants with reduced effector function
AU2020403913B2 (en) 2019-12-18 2024-10-10 F. Hoffmann-La Roche Ag Bispecific anti-CCL2 antibodies
WO2021154534A1 (en) * 2020-01-28 2021-08-05 Promab Biotechnologies, Inc. Plap-cd3 epsilon bispecific antibodies
MX2022013499A (es) * 2020-04-27 2023-01-16 Twist Bioscience Corp Bibliotecas de ácidos nucleicos variantes para coronavirus.
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
US20230374162A1 (en) * 2020-10-07 2023-11-23 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
CN114539415B (zh) * 2020-11-24 2024-02-02 普米斯生物技术(珠海)有限公司 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
CN112578117B (zh) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用
CN112698044B (zh) * 2021-03-23 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 靶向治疗后免疫状态评价装置及方法
EP4380631A4 (en) * 2021-08-04 2025-06-25 Abpro Corporation Cd3 targeting antibodies and uses thereof
EP4377360A4 (en) * 2021-09-17 2025-10-15 Adimab Llc Anti-cd3 antibodies
EP4413044A4 (en) * 2021-10-07 2025-10-22 Nat Res Council Canada ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS
WO2023060277A1 (en) * 2021-10-08 2023-04-13 Arbele Limited Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
CN114573705B (zh) * 2022-03-17 2024-05-14 杭州师范大学 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用
CN114605560B (zh) * 2022-03-30 2024-02-20 江苏蒙彼利生物科技有限公司 一种car-nk细胞及其制备方法与应用
CN116925232A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 靶向ceacam和cd3的多特异性抗体及其用途
CN115453124B (zh) * 2022-08-01 2025-11-25 中国科学院高能物理研究所 一种纳米颗粒表面多层蛋白冠成分的原位鉴定与定量方法
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
CN115960243B (zh) * 2023-01-09 2025-05-06 中国药科大学 靶向cd24和cd3的双特异性抗体及其应用
WO2024206568A2 (en) * 2023-03-31 2024-10-03 Ibio, Inc. Anti-cd3 antibodies
WO2025230233A1 (ko) * 2024-05-03 2025-11-06 국민대학교산학협력단 인간 cd3에 특이적인 항체 및 이의 용도
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504314A (ja) 2013-12-17 2017-02-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1629011T3 (da) * 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
SG182408A1 (en) * 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
HUE037720T2 (hu) * 2012-03-28 2018-09-28 Sanofi Sa Bradikinin B1 receptor ligandumok elleni antitestek
ME03675B (me) * 2013-07-05 2020-10-20 Genmab As Humanizovana ili himerna anтi-cd3 antiтela
PT3221356T (pt) * 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
CN120988137A (zh) * 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EP3091032A1 (en) * 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504314A (ja) 2013-12-17 2017-02-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法

Also Published As

Publication number Publication date
BR112019023111A2 (pt) 2020-07-28
RU2019139334A (ru) 2021-06-09
AU2025203086A1 (en) 2025-07-24
JP2020518650A (ja) 2020-06-25
CN110913895B (zh) 2024-04-02
CA3062825A1 (en) 2018-11-15
MX2024005009A (es) 2024-05-10
SG11201910096RA (en) 2019-11-28
US20200190189A1 (en) 2020-06-18
IL322042A (en) 2025-09-01
RU2019139334A3 (enExample) 2021-08-25
EP3621641A4 (en) 2021-03-03
CN110913895A (zh) 2020-03-24
KR102844399B1 (ko) 2025-08-11
KR20250121461A (ko) 2025-08-12
IL270366B2 (en) 2026-01-01
JP2023014324A (ja) 2023-01-26
AU2018266711A1 (en) 2019-11-28
KR20200053437A (ko) 2020-05-18
US20230151097A1 (en) 2023-05-18
IL270366A (en) 2019-12-31
MX2019013184A (es) 2020-02-07
US11542330B2 (en) 2023-01-03
CN118894936A (zh) 2024-11-05
WO2018208864A1 (en) 2018-11-15
CN118184781A (zh) 2024-06-14
CN118562001A (zh) 2024-08-30
AU2025203086A9 (en) 2026-03-05
AU2018266711B2 (en) 2025-02-06
JP2024032937A (ja) 2024-03-12
EP3621641A1 (en) 2020-03-18
JP7641262B2 (ja) 2025-03-06
SG10201912494TA (en) 2020-02-27
IL270366B1 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
JP7641262B2 (ja) 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法
JP7708911B2 (ja) 抗ｃｄ１３７抗原結合分子およびその使用
TW202325734A (zh) 抗cd3抗體
JP7686614B2 (ja) 癌の治療に用いるための抗ｃｄ１３７抗原結合分子
TW202446798A (zh) 抗ｃｄ２８抗體及其相關方法
RU2807040C2 (ru) Связывающие домены антитела к cd3 и содержащие их антитела, а также способы их получения и применения
HK40110891A (zh) 抗cd137抗原结合分子及其应用
HK40111428A (zh) 抗cd137抗原结合分子及其应用
BR122024026051A2 (pt) Anticorpo ou polipeptídeo de ligação a antígeno, seu uso, composição, e artigo de fabricação
HK40044036B (zh) 抗cd137抗原结合分子及其应用
HK40018510B (zh) 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法
HK40076755A (en) Anti-cd137 antigen-binding molecule for use in cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231124

R150 Certificate of patent or registration of utility model

Ref document number: 7393207

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150